Nghiên cứu tính nhạy cảm da của dung dịch xịt hỗ trợ điều trị viêm mũi xoang trên da lành của động vật thực nghiệm

Rhinosinusitis is a highly prevalent inflammatory condition of the upper respiratory tract, with global incidence rates ranging from 10-15%, and a growing trend in urban areas attributed to environmental pollution and allergies. While conventional treatments often rely on antibiotics and corticosteroids, their prolonged use carries risks of antibiotic resistance and systemic side effects. Consequently, there is increasing interest in adjunctive herbal-based formulations, particularly nasal sprays, which offer targeted delivery and reduced systemic exposure. Ensuring the safety of such topical products, especially their skin sensitization potential, is paramount before clinical application. This study addresses this critical need by evaluating the dermal reaction of a nasal spray solution, intended for the adjunctive treatment of rhinosinusitis, upon prolonged exposure to the skin in an experimental animal model.

Researchers in pharmaceutical sciences, toxicology, product development, and medical professionals involved in rhinosinusitis treatment.

This research rigorously evaluated the skin sensitization potential of a nasal spray solution developed for the adjunctive treatment of rhinosinusitis. Adhering strictly to the OECD Guideline for the Testing of Chemicals No. 406 (Skin Sensitization), the study employed a comprehensive experimental design using 210 guinea pigs. The method involved applying gauze pads impregnated with the nasal spray solution to the intact dorsal skin for 6-hour durations, with sensitization indices assessed at 24 and 48 hours post-removal. The findings revealed a sensitization index of 0, consistent with the GHS 2021 classification, and a complete absence of erythema or edema on the guinea pig skin throughout the study period. This conclusive result indicates that the nasal spray solution did not induce skin sensitization in the experimental animal model, underscoring its high dermal safety profile. These findings not only provide crucial scientific evidence supporting the safety of this topical formulation but also highlight the advantages of local nasal spray delivery over systemic treatments in managing rhinosinusitis, by mitigating potential systemic side effects. While the study confirms safety in an animal model, future investigations are necessary to conduct clinical trials with a larger patient cohort and analyze long-term effects and immune parameters to fully understand its efficacy and safety in human applications.